- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05467319
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS (FORGE)
July 19, 2022 updated by: Steven Bisch, Alberta Health Services, Calgary
Feasibility and Efficacy of Intravenous Ferric Derisomaltose to Correct Pre-operative Iron-deficiency Anemia in Patients Undergoing Gynecologic Oncology Surgery: a Pilot Randomized Double Blinded Parallel Group Placebo-controlled Study
Iron deficiency has been reported in up to 35% of patients with a gynecologic malignancy.
These patients often require surgical intervention to determine the stage and to treat their illness.
Blood transfusions occur in approximately 14% of these surgeries and carry immediate and long-term risks, including surgical site infection, cancer recurrence, and increased surgical length of stay.
Intravenous iron formulations have the potential to rapidly correct anemia in patients with gynecologic malignancy and potentially decrease blood transfusion and complications following surgery.
This prospective, randomized, placebo-controlled, double blind study aims to assess the effectiveness of preoperative ferric derisomaltose/iron isomaltoside compared to placebo in correcting preoperative hemoglobin in patients undergoing surgery for gynecologic malignancy.
The primary outcome is to assess the effectiveness of this formulation on pre-operative hemoglobin, and the feasibility of a larger, outcomes based, study in the future.
Exploratory outcomes are to assess the effect of preoperative intravenous iron on surgical length of stay, complications, and patient-reported quality of life.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
82
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- At least 18 years of age and signed written informed consent
Patients undergoing elective major surgery on the gynecologic oncology service with the following criteria will be considered for inclusion:
- The indication for the operation may be for suspected or proven gynecologic malignancy.
- Major surgery is defined as an operation of a duration of 1 hour or greater, with an Aletti complexity score of at least 1[19].
- The expected time from recruitment to surgery is at least 28 days.
- Screening haemoglobin less than 120g/L and transferrin saturation (TSAT) <20%
- Randomization and administration of study infusion a minimum of 21 days and maximum 90 days before planned operation.
- Negative pregnancy test for women of childbearing potential (within last 7 days), and agree to use effective form of contraception until 6 weeks post treatment (if applicable)
- Laboratory data used for determination of eligibility at the baseline visit must not be older than 4 weeks.
Exclusion Criteria:
- Known history of acquired iron overload, or family history of haemochromatosis or thalassemia, or TSAT >50%
- Known alternative cause for anemia (e.g. B12 or folate deficiency, or haemoglobinopathy)
- Known hypersensitivity to FDI or its excipients
- Temperature >38 C or patient on non-prophylactic antibiotics
- Known chronic liver disease or active hepatitis
- Received erythropoietin or IV iron therapy in previous 12 weeks
- If LFT's are ordered, either clinically indicated or for chemotherapy, and screening alanine transaminase (ALT) or aspartate transaminase (AST) is above three times the upper limit of normal (ULN) range
- Immunosuppressive therapy (for solid organ transplant), or renal dialysis (current, or planned within next 12 months)
- Unfit for elective surgery
- Pregnancy or lactation
- Unable to fully comprehend and/or perform study procedures
- Cervical cancer with a clinical stage of 2A or greater.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ferric derisomaltose
1000mg of intravenous Ferric derisomaltose/Iron isomaltoside in 100mL of normal saline will be administered 21-90 days prior to planned surgery for gynecologic malignancy as a single dose.
|
1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion
Other Names:
|
PLACEBO_COMPARATOR: Placebo
100mL of normal saline will be administered 21-90 days prior to planned surgery for gynecologic malignancy as a single dose.
|
100 mL of 0.9% normal saline (w/v) by intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preoperative hemoglobin level
Time Frame: 0 to 3 days prior to planned surgical intervention
|
Hemoglobin measured, in g/L, following intervention prior to planned gynecologic surgery.
|
0 to 3 days prior to planned surgical intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
September 30, 2022
Primary Completion (ANTICIPATED)
September 1, 2023
Study Completion (ANTICIPATED)
December 1, 2023
Study Registration Dates
First Submitted
July 18, 2022
First Submitted That Met QC Criteria
July 19, 2022
First Posted (ACTUAL)
July 20, 2022
Study Record Updates
Last Update Posted (ACTUAL)
July 20, 2022
Last Update Submitted That Met QC Criteria
July 19, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FORGEII
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynecologic Cancer
-
University of LouisvilleJames Graham Brown Cancer CenterCompleted
-
Shandong UniversityCompletedGynecologic Cancer | Gynecologic DiseaseChina
-
Washington University School of MedicineWashington University Department of Psychological and Brain SciencesTerminatedStage III Gynecologic Cancer | Stage IV Gynecologic CancerUnited States
-
Azienda Socio Sanitaria Territoriale degli Spedali...CompletedGynecologic Cancer | Surgery | Anesthesia | Hysterectomy | Gynecologic DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingGynecologic Cancer
-
IRCCS Policlinico S. MatteoNot yet recruiting
-
Fudan UniversityGuangzhou Burning Rock Dx Co., Ltd.Recruiting
-
Fox Chase Cancer CenterCompleted
-
University Hospital, GenevaCompletedGynecologic CancerSwitzerland
-
Fudan UniversityGuangzhou Burning Rock Bioengineering Ltd.Active, not recruiting
Clinical Trials on Ferric Derisomaltose Injection
-
Hallym University Medical CenterRecruiting
-
Oregon Health and Science UniversityNot yet recruiting
-
Children's Hospital Los AngelesNot yet recruitingAnemia | Iron Deficiency Anemia | Anemia, Iron Deficiency | IDA - Iron Deficiency AnemiaUnited States
-
University of GlasgowPharmacosmos A/S; British Heart Foundation; NHS Greater Glasgow and ClydeCompletedChronic Heart Failure | Iron Deficiency | Left Ventricular Systolic DysfunctionUnited Kingdom
-
West China HospitalNot yet recruiting
-
Thomas Jefferson UniversityJawaharlal Nehru Medical College; Children's Investment Fund Foundation; S. Nijalingappa... and other collaboratorsActive, not recruitingIron Deficiency Anemia | Infant, Low Birth Weight | Anemia of PregnancyIndia
-
Thomas Jefferson UniversityJawaharlal Nehru Medical College; S. Nijalingappa Medical College; Raichur Institute...Active, not recruitingAutism Spectrum Disorder | Iron Deficiency Anemia | Neurodevelopmental AbnormalityIndia
-
Thomas Jefferson UniversityJawaharlal Nehru Medical CollegeActive, not recruitingIron Deficiency Anemia | Child Development | Iron Deficiency Anemia of Pregnancy | Iron Deficiency Anemia Treatment | Neurodevelopmental Disorder of Foetus | Fetal Neurodevelopmental DisorderIndia
-
Pharmacosmos A/SRecruitingIron Deficiency, Anaemia in ChildrenUnited States
-
AHS Cancer Control AlbertaNot yet recruitingGynecologic Cancer | Iron-deficiency | AnemiaCanada